浩欧博收盘上涨1.77%，滚动市盈率162.23倍，总市值56.18亿元

Company Overview - Jiangsu Haooubo Biomedicine Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company holds 226 product registration certificates and 57 patents, and is recognized as a high-tech enterprise with multiple awards for innovation and creditworthiness [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% year-on-year, with a gross margin of 57.98% [2] Market Position - As of May 29, the company's stock closed at 89.1 yuan, with a rolling price-to-earnings (PE) ratio of 162.23, significantly higher than the industry average PE of 49.64 and median PE of 36.36, placing the company at rank 114 in the industry [1][3] - The total market capitalization of the company is 5.618 billion yuan [1] Shareholder Information - As of March 31, 2025, the company had 3,065 shareholders, an increase of 30 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]